Alcohol and nicotine addiction are frequently co-morbid. The nicotinic acetylcholine receptors (nAChRs) are critical for both alcohol and nicotine addiction mechanisms, since nAChR drugs that reduce nicotine consumption have been shown to also reduce alcohol consumption. Sazetidine-A, a pre-clinical nAChR drug with agonist and desensitizing effects at a4b2 and a7 nAChRs, has been reported to reduce alcohol consumption and nicotine self-administration in rats when administered at high doses. However, this effect has not been replicated in mice. In this study, we examined the effect of sazetidine-A on alcohol and nicotine consumption in male and female mice utilizing voluntary oral consumption procedures previously developed in our lab. We found that sazetidine-A (1 mg/kg, i.p) reduced overnight alcohol consumption, but did not affect nicotine consumption when presented either alone or concurrently with alcohol. Sazetidine-A did not reduce water or saccharin consumption at any dose tested. In a chronic coconsumption experiment in which either alcohol or nicotine was re-introduced after one week of forced abstinence, sazetidine-A attenuated post-abstinence consumption of alcohol but not nicotine. Sazetidine-A also significantly reduced alcohol consumption in an acute, binge drinking-in-the-dark procedure. Finally, we tested the effect of sazetidine-A on alcohol withdrawal, and found that sazetidine-A significantly reduced handling-induced convulsions during alcohol withdrawal. Collectively, these data suggest a novel role for the nAChR targets of sazetidine-A in specifically mediating alcohol consumption, separate from the involvement of nAChRs in mediating nicotine consumption. Delineation of this pathway may provide insight into novel therapies for the treatment of alcohol use disorders.
Introduction
Nicotine and alcohol are two of the most widely used addictive drugs, and their use is frequently co-morbid. Alcohol abuse is much more common among smokers compared with non-smokers, and up to 80e90% of people with alcohol dependence also smoke cigarettes (Anthony and Echeagaray-Wagner, 2000; Batel et al., 1995; DiFranza and Guerrera, 1990) . Additionally, numerous epidemiological reports have demonstrated that the use of either alcohol or nicotine increases the use of the other drug (Barrett et al., 2006; Chen et al., 2002; Harrison et al., 2008; Weitzman and Chen, 2005) . Nicotine and alcohol both mediate their reinforcing properties by modulating the release of dopamine (DA) from ventral tegmental (VTA) neurons that project to the nucleus accumbens (NAc) (Balfour et al., 1998; Gessa et al., 1985; Mifsud et al., 1989; Weiss et al., 1993) . Nicotine and alcohol addiction are heritable and share common genetic factors and neuromolecular mechanisms, including the involvement of the nicotinic acetylcholine receptors (nAChRs) (Hendrickson et al., 2013; Li and Burmeister, 2009; Li et al., 2003) .
The nAChRs are ligand-gated cation channels that are activated by the endogenous ligand acetylcholine (for review, see (Albuquerque et al., 2009) ). Eleven nAChR subunits are expressed in the brain (a2-7, a9-10, b2-4) that combine to form pentameric channels with distinct pharmacological properties and physiological functions (Albuquerque et al., 2009; Wonnacott et al., 2006) .
The nAChRs are primarily located on neuronal cell bodies and presynaptic terminals, and thus are positioned to directly modulate cell excitability in the mesolimbic reward circuitry. Activation of nAChRs excites VTA dopaminergic neurons to initiate DA release in the NAc. The nAChRs are well-known to play a critical role in nicotine reinforcement (for reviews, see (Changeux, 2010; de Kloet et al., 2015) ). Genetic and pharmacological evidence also strongly implicate a role for the nAChRs in alcohol addiction (for reviews, see (Chatterjee and Bartlett, 2010; Davis and de Fiebre, 2006; Hendrickson et al., 2013) ), but the identity of the specific nAChR subtypes that are critical for alcohol addiction remain unclear. Unlike nicotine, alcohol does not directly activate nAChR channels, but alters ligand-induced nAChR currents, depending on the subunit composition of the receptor (Covernton and Connolly, 1997; Nagata et al., 1996; Yu et al., 1996) . Additionally, voluntary alcohol consumption increases acetylcholine levels in the VTA in rats, (Larsson et al., 2005) , and cholinergic signaling through nAChRs contributes to DA release in the NAc and to alcohol reward and reinforcement in rats and mice (Blomqvist et al., 1993 (Blomqvist et al., , 1996 Kuzmin et al., 2009; Soderpalm et al., 2000) . Therefore, cholinergic signaling through nAChRs is a critical component of alcohol addiction.
Most nAChR-acting drugs that reduce nicotine consumption are also capable of reducing alcohol consumption. The non-specific nAChR antagonist mecamylamine consistently reduces nicotine consumption (Corrigall and Coen, 1989; DeNoble and Mele, 2006; Glick et al., 1996; Rose et al., 1994) , decreases alcohol consumption and preference in rodents (Blomqvist et al., 1996 (Blomqvist et al., , 2002 Farook et al., 2009; Ford et al., 2009; Hendrickson et al., 2009 ) and blocks alcohol-induced DA release in the NAc (Blomqvist et al., 1993 (Blomqvist et al., , 1997 Ericson et al., 1998) . Cytisine, an a4b2 partial agonist, has also been shown to reduce both alcohol and nicotine consumption in mice (Hendrickson et al., 2009 ). More recently, varenicline, an a4b2 partial agonist developed for smoking cessation, was found to reduce both nicotine and alcohol consumption in mice (Hendrickson et al., 2010) , rats (Chatterjee et al., 2011; Steensland et al., 2007) , and humans (Litten et al.; McKee et al., 2009; Mitchell et al., 2012) . The mechanism by which mecamylamine and varenicline reduce alcohol consumption and the specific nAChRs required for this effect remains unclear. In contrast, dihydro-beta-erythroidine (DHbE), a competitive antagonist of b2-and b4-containing nAChRs, attenuates the behavioral effects of nicotine in vivo (Damaj et al., 1995; Walters et al., 2006; Watkins et al., 1999) , but does not reduce alcohol consumption (Kuzmin et al., 2009; Le et al., 2000) . These pharmacological data coincide with studies of mice with genetic deletions for the a4 or b2 nAChR subunit, which show that a4 and b2 knock-out (KO) mice do not self-administer nicotine (Picciotto et al., 1998; Pons et al., 2008) , and that a4, but not b2, knock-out mice consume less alcohol compared to wild-type mice (Dawson et al., 2013; Hendrickson et al., 2011) . Therefore, different nAChRs subtypes appear to have differential roles in mediating nicotine-specific and alcohol-specific mechanisms.
Sazetidine-A is a pre-clinical nAChR drug that has recently been shown to reduce alcohol consumption and i.v. nicotine selfadministration in rats (Johnson et al., 2012; Levin et al., 2010; Rezvani et al., 2010) . Similar to other nAChR drugs, the mechanism by which sazetidine-A reduces alcohol consumption is unclear. Sazetidine-A was originally described as a "silent desensitizer" of a4b2 nAChRs (Xiao et al., 2006) , but has since been discovered to have differential specificity depending on the subunit composition of the a4b2 pentamer. Sazetidine-A fully activates the a4 2 b2 3 stoichiometry (Xiao et al., 2006; Zwart et al., 2008) and has negligible activity at a4 3 b2 2 nAChRs (Campling et al., 2013; Eaton et al., 2014; Zwart et al., 2008) , due to the selectivity of sazetidine-A at the a4/b2 but not the a4/a4 interface (Eaton et al., 2014; Wang et al., 2015; Zwart et al., 2008) . In addition, sazetidine-A has full agonist and desensitizing activity at a7 nAChRs (Brown and Wonnacott, 2015) , full agonist activity at a3b4* nAChRs, and partial agonist activity at a4b4* and a6b2* receptors (* denotes the possible presence of additional subunits in the receptor pentamer) (Campling et al., 2013; Kuryatov and Lindstrom, 2011) . Like nicotine, sazetidine-A causes long-term desensitization of nAChRs that can potentially last for hours (Campling et al., 2013; Eaton et al., 2014; Paradiso and Steinbach, 2003) . Moreover, sazetidine-A accumulates in the brain and can occupy b2-containing nAChRs with a dissociation half-life of 8e24 h (Caldarone et al., 2011) .
In rat studies showing that sazetidine-A reduces alcohol and nicotine consumption, the doses used also caused reduced consumption of food and reduced intake of saccharin solution , suggesting potential off-target effects of sazetidine-A. Additionally, the effect of sazetidine-A has never been tested in mice, nor on voluntary, oral co-consumption of alcohol and nicotine presented concurrently. In this study, we tested the effect of sazetidine-A on alcohol and nicotine consumption in male and female mice using models of voluntary, oral consumption that we developed and have described previously (O'Rourke et al., 2016) . Here, we show for the first time that sazetidine-A, at a dose that does not affect water or saccharin consumption, reduces alcohol consumption in mice without affecting nicotine consumption. We found that sazetidine-A also reduced handling-induced convulsions during alcohol withdrawal, revealing a potential mechanism by which sazetidine-A reduces alcohol consumption.
Materials and methods

Animals and drugs
Adult male and female mice a minimum of 8 weeks old were used in all experiments. C57BL/6 mice were purchased from Jackson Laboratory (Sacramento, CA) and acclimated to the facility for a minimum of six days before behavioral experiments. All mice were group housed under a standard 12 h light/dark cycle until the start of experiments, after which they were individually housed. All animal procedures were performed in accordance with the Institutional Animal Care and Use Committee at the University of Minnesota, and conformed to NIH guidelines.
Alcohol (Decon Labs, King of Prussia, PA), and nicotine tartrate salt (Acros Organics, Thermo Fisher Scientific, Chicago, IL) were mixed with tap water to the concentrations reported for each experiment. The concentrations of nicotine are reported as free base, and nicotine solutions were not filtered or pH adjusted. Neither the alcohol nor nicotine solutions contained sweetener. Sazetidine-A dihydrochloride was purchased from Tocris Bioscience (Bio-Techne, Minneapolis, MN), and made fresh for each experiment by dissolving in 0.9% saline and was not filtered or pH adjusted.
2.2. Experiment 1A and 1B: the effect of sazetidine-A on water and saccharin consumption Experiment 1A: Drug naïve male C57BL/6 mice were singly housed and underwent sequential experiments to first assess the effect of sazetidine-A on consumption of water only, followed by saccharin consumption in a continuous 24-h access two-bottle choice procedure. Food and water were freely available at all times throughout the procedures. For the water consumption portion, one bottle of water was available at all times. Three intraperotineal (i.p.) saline injections were administered on Monday, Wednesday, and Friday, once per day, to habituate the mice to injections. The following Monday, mice received an injection of either sazetidine-A (1 mg/kg, i.p.) or saline immediately prior to the dark cycle. The weight of the water bottle was measured 1 and 4 h into the dark cycle, and again the next morning. Two days later, mice began a continuous two-bottle choice procedure with access to a bottle of water and a bottle containing 0.5 mM saccharin dissolved in water at all times. The positions of the bottles were alternated every 2 days to account for side preferences. On day 5, mice were divided into two treatment groups based on their average saccharin consumption, and received either sazetidine-A (1 mg/kg, i.p.) or saline immediately prior to the dark cycle. The weights of the water and saccharin bottles were measured 1 and 4 h into the dark cycle, and again the next morning.
Experiment 1B: A separate group of naïve male C57BL/6 mice were used to assess the effect of 2 and 3 mg/kg sazetidine-A on water and saccharin consumption using the identical procedure described in Experiment 1A. The effect of 2 mg/kg sazetidine-A on water only consumption, followed by 0.5 mM saccharin two-bottle choice was performed exactly as described for 1 mg/kg sazetidine-A in Experiment 1A. One week later, this same group of mice underwent the procedure again to test the effect of 3 mg/kg sazetidine-A on water consumption followed by saccharin consumption. The mice received free access to food and water during the interim week. The treatment groups were kept the same for the water and saccharin consumption portions across sazetidine-A concentrations.
2.3. Experiment 2A and 2B: the effect of sazetidine-A on alcohol or nicotine two-bottle choice consumption Experiment 2A Alcohol two-bottle choice: Drug naïve C57BL/6 male and female mice were singly housed in double grommet cages and underwent a continuous access alcohol two-bottle choice procedure that we have previously described (O'Rourke et al., 2016) . Briefly, mice were presented with a bottle of water and a bottle of alcohol. The alcohol was presented at the following concentrations for 4 days each: 3, 6, 10, 14, and 20% v/v. For the remainder of the procedure, 20% alcohol and water were presented at all times. During week 4, three i.p. saline injections were administered, separated by 48 h each, to habituate the mice to injections. During week 5 (48 h after the final saline injection), mice were divided into two equal treatment groups based on their average alcohol consumption after the final saline injection. Mice were then pretreated with sazetidine-A (1 mg/kg, i.p.) or saline 1 h prior to the dark cycle, and the alcohol and water bottles were weighed at the time of injection and again the next morning. A second injection of sazetidine-A (1 mg/kg) or saline was administered 48 h after the first injection, and bottles were again weighed at the time of injection and the next morning. The mice were presented with 20% alcohol and water throughout the 48 h period between injections.
Experiment 2B Nicotine two-bottle choice: A separate group of drug naïve C57BL/6 male and female mice were singly housed in double grommet cages and underwent a continuous access nicotine two-bottle choice procedure that we have previously described (O'Rourke et al., 2016) . Mice were presented with a bottle of water and a bottle containing nicotine dissolved in water. During week 1, nicotine was presented at the following concentrations for 2 days each: 5, 10, and 15 mg/mL. For the remainder of the procedure, 30 mg/mL nicotine and water were presented at all times. During week 3, mice were habituated to 3e4 i.p. saline injections separated by 48 h each. At the end of week 3 (48 h after the final saline injection), the mice were divided into two treatment groups.
Sazetidine-A (1 mg/kg, i.p.) or saline was administered 1 h prior to the dark cycle, and the nicotine and water bottle were weighed at the time of injection and again the next morning. A second injection of sazetidine-A (1 mg/kg, i.p.) or saline was administered 48 h after the first injection, and bottles were again measured at the time of injection and the next morning. The mice were presented with 30 mg/mL nicotine and water during the 48 h period between injections. Nicotine consumption was calculated as mg/kg consumed.
2.4. Experiment 3: the effect of sazetidine-A on alcohol and nicotine three-bottle choice consumption Alcohol and nicotine three-bottle choice: Drug naïve male and female C57BL/6 mice underwent an intermittent access threebottle choice consumption procedure based on a method we have described previously (O'Rourke et al., 2016) . Briefly, alcohol, nicotine, and water bottles were presented for 24 h beginning each morning on Monday, Wednesday, and Friday. During week 1, the concentrations of alcohol and nicotine increased every session, beginning with 3% alcohol and 5 mg/mL nicotine on Monday, 6% alcohol and 10 mg/mL nicotine on Wednesday, and 10% alcohol and 15 mg/mL nicotine on Friday. For the rest of the procedure, mice were presented with 20% alcohol, 30 mg/mL nicotine, and water every Monday, Wednesday and Friday. Mice had access to water only at all other times. During week 5, mice received i.p. saline injections on Monday, Wednesday, and Friday immediately prior to the dark cycle to habituate to the injection procedure. On Monday of week 6, mice were divided into two treatment groups and injected with either sazetidine-A (1 mg/kg, i.p.) or saline immediately prior to the dark cycle. On Wednesday the same treatment groups were injected a second time with either sazetidine-A (1 mg/kg, i.p.) or saline immediately prior to the dark cycle. Bottles were measured at the time of injection and again the next morning.
2.5. Experiment 4A and 4B: the effect of sazetidine-A on alcohol or nicotine consumption after abstinence Experiment 4A Alcohol abstinence: Drug naïve male C57BL/6 mice underwent a continuous access three-bottle choice consumption experiment based on a procedure we described previously (O'Rourke et al., 2016) . Briefly, mice were presented with three bottles containing alcohol, nicotine, or water, with each set of concentrations presented for 3 days. The alcohol was presented at the following concentrations: 3, 10, and 20% v/v, and for nicotine: 5, 15, and 30 mg/mL. For the rest of the procedure, 20% alcohol, 30 mg/ mL nicotine, and water were presented continuously. Mice received 3 i.p. saline injections during week 2 to habituate them to injections. During week 4, the alcohol bottle was removed and the nicotine and water bottles remained available. At the beginning of week 5, mice were divided into two treatment groups and received an injection of either sazetidine-A (1 mg/kg, i.p.) or saline immediately prior to the dark cycle during which the alcohol bottle was re-introduced. All bottles were measured at the time of injection and again the next morning. That evening, the same treatment groups again received an injection of sazetidine-A (1 mg/kg, i.p.) or saline immediately prior to the dark cycle. Bottles were measured at the time of injection and again the next morning. Experiment 4B Nicotine abstinence: A separate group of drug naïve male C57BL/6 mice underwent a procedure similar to Experiment 4A, except that the nicotine bottle was removed during the abstinence week instead of the alcohol bottle.
Experiment 5: the effect of sazetidine-A on acute alcohol binge consumption
Alcohol drinking-in-the-dark: Drug naïve male C57BL/6 mice were singly housed and received 3 i.p. saline injections during week 1, separated by 48 h each to habituate them to the injections. During week 2, the binge, drinking-in-the-dark alcohol consumption experiment was performed based on the protocol of (Rhodes et al., 2005) . On days 1e3, mice were presented with a single bottle of 20% alcohol for 2 h, beginning 3 h into the dark cycle. The bottle was weighed before and after each session. Mice had access to water only at all other times. On day 4, mice were pretreated with sazetidine-A (1 mg/kg, i.p.) or saline immediately prior to the dark cycle. The alcohol bottle was presented for a 4 h session, beginning 3 h into the dark cycle.
Experiment 6: the effect of sazetidine-A on acute alcohol withdrawal
Handling-Induced Convulsions (HICs): Alcohol withdrawal was induced in drug naïve male C57BL/6 mice by injecting alcohol once per day for 7 days prior to measuring handling-induced convulsions. For the first 5 days, mice received an injection of 3 g/kg alcohol (i.p.) at the same time each day, and on days 6 and 7 mice received an injection of 4 g/kg alcohol. One hour before the final alcohol injection, mice were pretreated with either sazetidine-A (1 mg/kg, i.p.) or saline. HICs were measured based on the protocol of (Goldstein, 1972; Metten et al., 1998) . Mice were lifted by the tail and observed for convulsions before and after a brief 360-degree spin. Baseline HICs were measured immediately prior to the first alcohol injection of Day 1. HICs were then measured 2 h after the final alcohol injection and repeated once per hour for a total of 10 measurements. HIC scores were measured by an experimenter blinded to the treatment conditions, and were scored from 0 to 5, according to a scoring system modified from (Farook et al., 2008) , which is detailed in Table 1 .
Statistical analysis
Consumption was calculated as g/kg for water or alcohol, and mg/kg for saccharin or nicotine. Preference was calculated as the amount of fluid (g) consumed from the bottle of interest divided by overall fluid consumed from all available bottles. All analyses were calculated using Prism 6.0 (GraphPad, La Jolla, CA). For each experiment, the average alcohol (g/kg) and nicotine consumption (mg/kg) for each concentration was calculated based on the weights of the bottles, the density of the solution (for alcohol only), and the weight of the individual mouse. The percent preference for the alcohol, nicotine, and water bottles was calculated as the weight of the bottle, divided by the weights of all three bottles combined X 100. Outliers were detected using the Grubbs test. The effects of sazetidine-A on water and saccharin consumption and on binge alcohol consumption were calculated using a Student's t-test. Consumption and preference in the two-and three-bottle choice experiments were analyzed using two-way repeated measures ANOVA with a Bonferonni multiple comparison post-hoc test. The effect of sazetidine-A on HIC scores over time was analyzed via two-way repeated measures ANOVA with a Sidak's multiple comparisons test. For area under curve analysis, all HIC scores were normalized to the baseline score for each animal, and the corrected values were summed to give the animal's withdrawal severity score (Kozell et al., 2008; Metten and Crabbe, 1994) .
Results
3.1. Experiments 1A and 1B: sazetidine-A does not reduce water or saccharin consumption at any dose tested
We first tested the whether sazetidine-A would reduce water and saccharin consumption in male C57BL/6 mice in sequential water and saccharin consumption tests (Fig. 1A) . In Experiment 1A, we found that pretreatment with 1 mg/kg sazetidine-A had no effect on water [t ¼ 1.37, P ¼ .19] (Fig. 1B) or 0.5 mM saccharin consumption [t ¼ 0.13, P ¼ .895] after a 4 h period compared with saline pretreatment (Fig. 1C) . Total overnight water [t ¼ 0.38, P ¼ .71] (Fig. 1D ) and saccharin consumption [t ¼ 0.998, P ¼ .34] (Fig. 1E) were also not reduced by 1 mg/kg sazetidine-A. In Experiment 1B, we increased the dose of sazetidine to 2 mg/kg and then to 3 mg/kg, and found that neither dose reduced water [t ¼ 0.55, P ¼ .59 for 2 mg/kg; t ¼ 0.75, P ¼ .46 for 3 mg/kg] (Fig. 1F ) or saccharin consumption [t ¼ 0.56, P ¼ .58 for 2 mg/kg; t ¼ 0.31, P ¼ .76 for 3 mg/kg] (Fig. 1G) after a 4 h period compared with saline pretreatment. There was an increase in overnight water consumption after treatment with 2 mg/kg sazetidine-A [t ¼ 2.32, P ¼ .032], but not with 3 mg/kg sazetidine-A [t ¼ 1.23, P ¼ .235] (Fig. 1H) . Overnight saccharin consumption was also not decreased by either dose [t ¼ 0.68, P ¼ .50 for 2 mg/kg; t ¼ 0.33, P ¼ .74, for 3 mg/kg] compared with saline pretreatment (Fig. 1I). 3.2. Experiment 2A and 2B: sazetidine-A reduces alcohol but not nicotine consumption in separate two-bottle choice consumption procedures As 1 mg/kg sazetidine-A was the lowest dose we tested that did not affect water or saccharin consumption, we used 1 mg/kg sazetidine-A for all alcohol and nicotine consumption experiments.
In Experiment 2A, we tested the effect of sazetidine-A (1 mg/kg) on alcohol consumption in a continuous access two-bottle choice procedure. Following 4 weeks of continuous alcohol consumption, we treated mice with two injections of sazetidine-A (1 mg/kg i.p.) or saline separated by 48 h, and measured overnight consumption of 20% alcohol. Sazetidine-A significantly reduced alcohol consumption in males [F treatment (1,13) ¼ 28.04, P ¼ .02] (Fig. 2A) , and females [F treatment (1,47) ¼ 6.91, P ¼ .048] compared with saline treatment (Fig. 2B ). There was a significant effect of session in females where overall consumption in both treatment groups increased after the second injection [F session (1,47) ¼ 1.71, P ¼ .015]. There was no significant reduction in alcohol preference upon treatment with sazetidine-A in males [F treatment (1, 13 In Experiment 2B, we tested the effect of sazetidine-A on nicotine consumption in a continuous access two-bottle choice procedure in a separate group of mice. Following 3 weeks of continuous nicotine consumption, we treated mice with two injections of 1 mg/kg sazetidine-A separated by 48 h and measured (Fig. 2C ). There was a significant effect of session where nicotine consumption in both sazetidine-A and saline treatment groups increased after the second injection [F session (1,18) ¼ 7.12, P ¼ .25].
We found no significant difference in male nicotine preference between the treatment groups [F treatment (1,18) ¼ 0.80, P ¼ .66]. For females, there was also no effect of sazetidine-A on nicotine consumption [F treatment (1,18) ¼ 3.14, P ¼ .30], although there was a significant overall interaction where overnight nicotine consumption increased in the saline group after the second injection [F treatment x session (1,18) ¼ 7.88, P ¼ .04; post-hoc test P < .01] (Fig. 2D ). There was a significant overall effect of session on female nicotine preference, where both sazetidine-A and saline treated groups had higher nicotine preference after the second session 3.3. Experiment 3: sazetidine-A reduces alcohol but not concurrent nicotine consumption in a chronic, intermittent access three-bottle choice procedure
In Experiment 3, we tested the effect of sazetidine-A on concurrent alcohol and nicotine co-consumption in an intermittent access three-bottle choice procedure to assess whether concurrent access to alcohol and nicotine influenced the effect of sazetidine-A.
Following 5 weeks of 20% alcohol and 30 mg/mL nicotine coconsumption, we treated mice with two injections of 1 mg/kg sazetidine-A or saline separated by 48 h and measured overnight consumption of alcohol and nicotine. In male mice, sazetidine-A reduced alcohol consumption [F treatment (1,13) ¼ 34.84, P ¼ .009] (Fig. 3A) and preference [F treatment (1,13) ¼ 34.77, P ¼ .007] (Fig. 3B ) compared with saline treatment. In females, sazetidine-A reduced alcohol consumption [F treatment (1,13) ¼ 57.63, P ¼ .0001] (Fig. 3C) (Fig. 3D ) compared with saline treatment. There was a significant effect of session in females where overall alcohol preference in sazetidine-A and saline treated groups increased after the second injection [F session (1,13) ¼ 21.37, P < .0001].
Interestingly, treatment with sazetidine-A did not significantly affect concurrent overnight nicotine consumption [F treatment (1,13) ¼ 7.15, P ¼ .122] (Fig. 3E) , or preference [F treatment (1,13) ¼ 9.74, P ¼ .158] (Fig. 3F ) in male mice compared with saline treatment. Sazetidine-A also did not affect female nicotine consumption [F treatment (1,13) ¼ 1.51, P ¼ .505] (Fig. 3G) or preference [F treatment (1,13) ¼ 6.23, P ¼ .099] compared with saline treatment (Fig. 3H) .
Experiment 4A and 4B: sazetidine-A reduces only alcohol consumption after alcohol or nicotine abstinence
In experiment 4A, we tested the ability of sazetidine-A to reduce alcohol consumption after one week of forced abstinence in a continuous access three-bottle choice procedure in male mice. After 3 weeks of alcohol and nicotine co-consumption, the alcohol bottle was removed during week 4, and 1 mg/kg sazetidine-A or saline was administered immediately prior to re-introduction of the alcohol bottle at the beginning of week 5. A second injection of sazetidine-A was administered 24 h later. Sazetidine-A reduced overnight alcohol consumption in both sessions [F treatment (1,27) ¼ 15.71, P ¼ .0107] compared with saline treatment, and there was a significant overall effect of session where both sazetidine-A and saline treated mice consumed less alcohol after the first injection compared with the second session [F session (1,27) ¼ 3.78, P ¼ .049] (Fig. 4A) . Sazetidine-A also reduced alcohol preference in both sessions [F treatment (1,27) ¼ 14.86, P ¼ .0141] compared with saline treatment. Similar to previous experiments, sazetidine-A did not affect concurrent nicotine consumption [F treatment (1,27) ¼ 1.10, P ¼ .40] compared with saline treatment (Fig. 4B) . Nicotine preference was also not different between the treatment groups [F treatment (1,27) ¼ 2.49, P ¼ .18], but there was a significant effect of session where both sazetidine-A and saline treated groups had a higher preference for nicotine after the second injection [F session (1,27) ¼ 14.63, P ¼ .007]. 1) and again 48 h later (session 2). *P < .05 for an effect of treatment using a two-way repeated measures ANOVA. B) Average overnight alcohol consumption in females after treatment with 1 mg/kg sazetidine-A or saline. *P < .05 for an effect of treatment or session. Male C57BL/6 n ¼ 8 sazetidine-A and n ¼ 7 saline treated mice, female C57BL/6 n ¼ 26 sazetidine-A and n ¼ 23 saline treated mice. C) Average overnight two-bottle choice nicotine consumption in males after treatment with 1 mg/kg sazetidine-A or saline. *P < .05 for an effect of session using a two-way repeated measures ANOVA. D) Average overnight nicotine consumption females after treatment with 1 mg/kg sazetidine-A or saline *P < .05 for an effect of session. Male and female C57BL/6 n ¼ 10 per group. Fig. 3 . Sazetidine-A reduces alcohol but not concurrent nicotine consumption in a chronic, intermittent access three-bottle choice procedure. A) Average overnight alcohol consumption and B) preference in males after treatment with 1 mg/kg sazetidine-A or saline. **P < .01 for an effect of treatment using a two-way repeated measures ANOVA. C) Average overnight alcohol consumption and D) preference in females after treatment with 1 mg/kg sazetidine-A or saline. ***P < .001 for an effect of treatment, ****P < .0001 for an effect of session. E) Average nicotine consumption and F) preference in males. G) Average nicotine consumption and H) preference in females. C57BL/6 n ¼ 7e8 per group per sex. Next, we tested the effect of sazetidine-A on alcohol and nicotine consumption after one week of forced nicotine abstinence in a continuous access three-bottle choice procedure in male mice. After 3 weeks of alcohol and nicotine co-consumption, the nicotine bottle was removed during week 4, and 1 mg/kg sazetidine-A or saline was administered immediately prior to re-introduction of the nicotine bottle at the beginning of week 5. A second injection of sazetidine-A was administered 24 h later. In this procedure, there was a significant overall interaction on alcohol consumption, where mice treated with sazetidine-A consumed less alcohol after the second injection (Fig. 4C) [F session x treatment (1,27) ¼ 2.88, P ¼ .034, post-hoc P < .05]. Sazetidine-A did not influence alcohol preference [F treatment (1, 27 ) ¼ 9.20, P ¼ .61] compared with saline treatment. Interestingly, sazetidine-A did not affect concurrent nicotine consumption after nicotine re-exposure [F treatment (1,27) ¼ 1.76, P ¼ .41] compared with saline treatment (Fig. 4D) . There was also no difference in nicotine preference across the treatment groups, but there was a significant overall effect of session where both sazetidine-A and saline treated groups had decreased preference for nicotine after the second injection [F session (1,27) ¼ 20.06, P < .0001].
3.5. Experiment 5: sazetidine-A reduces acute alcohol consumption in a binge, drinking-in-the-dark procedure
We tested whether sazetidine-A would reduce acute binge alcohol consumption in a drinking-in-the-dark procedure (Rhodes et al., 2005) . Alcohol consumption was similar between the saline and sazetidine-A groups prior to treatment (Fig. 5A) . On day 4, mice pretreated with sazetidine-A (1 mg/kg, i.p.) 1 h prior to the 4 h binge session consumed significantly less alcohol [t¼2.33, P ¼ .028] compared with saline pretreatment (Fig. 5B) .
Experiment 6: sazetidine-A reduces alcohol withdrawal signs
We tested whether sazetidine-A would affect alcohol withdrawal by measuring HIC scores during withdrawal. Compared to baseline HIC scores prior to alcohol injection, animals pretreated with either saline or sazetidine-A developed a time-dependent increase in HIC scores beginning 6 h after the final alcohol injection [F session x treatment (11,143) ¼ 3.81, P ¼ .008, post-hoc test for saline treatment P < .001 for 6hr and P < .0001 for 7hr-12hr; for sazetidine-A treatment P < .05 for 6hr, P < .0001 for 7e9hr, and P < .001 for 10hr-11hr]. Animals pretreated with sazetidine-A developed significantly lower HIC scores over time compared to saline-treated controls [F session x treatment (11,143) ¼ 3.81, P ¼ .008, post-hoc test P < .05 for 9hr, P < .01 for 12hr] (Fig. 6A) . Additionally, overall alcohol withdrawal severity was significantly reduced in animals pretreated with sazetidine-A [t ¼ 2.78, P ¼ .016] (Fig. 6B ).
Discussion
In this study, we investigated the effect of sazetidine-A on alcohol and nicotine single-drug consumption and co-consumption procedures utilizing voluntary, oral consumption models. Alcohol and nicotine oral consumption procedures are widely used in mice (Farook et al., 2009; Klein et al., 2004; Rhodes et al., 2005; Robinson et al., 1996; Yoneyama et al., 2008) and we have recently published our model of oral alcohol and nicotine co-consumption in mice (O'Rourke et al., 2016) . We found that 1 mg/kg sazetidine-A reduces alcohol consumption but does not reduce the amount of nicotine consumed in both male and female mice in all procedures tested. In the few studies that have investigated the effect of sazetidine-A on alcohol or nicotine consumption in separate procedures, male rats treated with 1 or 3 mg/kg sazetidine-A consume less alcohol, and male rats self-administer less nicotine intravenously only if treated with higher doses of sazetidine-A (3e6 mg/kg) (Johnson et al., 2012; Levin et al., 2010; Rezvani et al., 2010) . It is possible that factors aside from the sazetidine-A dose may contribute to the difference between our findings and those previously published, such as the nature of the consumption procedure (operant intravenous nicotine self-administration versus non-operant voluntary oral consumption), the length of exposure to both drugs, and the species used (rats versus mice). At the higher doses that were reported to reduce nicotine intake in rats, sazetidine-A also reduced food and fluid consumption Rezvani et al., 2011) . We speculate that the reduction in nicotine consumption reported in those studies may be primarily due to a non-specific decrease in consummatory behavior. We found that sazetidine-A administered Fig. 4 . Sazetidine-A reduces only alcohol consumption after alcohol or nicotine abstinence. A) Average overnight alcohol consumption in male mice treated with 1 mg/kg sazetidine-A or saline prior to re-introduction of the alcohol bottle (session 1) and again 24 h later (session 2). *P < .05 for an effect of treatment or session using a two-way repeated measures ANOVA. B) Average overnight nicotine consumption. Male C57BL/6 n ¼ 14e15 per group. C) Average overnight alcohol consumption in male mice treated with sazetidine-A or saline immediately prior to re-introduction of the nicotine bottle (session 1) and again 24 h later (session 2). *P < .05 for an overall effect of treatment and session. D) Average overnight nicotine consumption. Male C57BL/6 n ¼ 14e15 per group. Fig. 5 . Sazetidine-A reduces alcohol consumption in a binge, drinking-in-the-dark procedure. A) Average alcohol consumption during the 2 h sessions on days 1e3 of the drinking-in-the-dark procedure. No pretreatment was given during these sessions. B) Average 4 h alcohol consumption after pretreatment with 1 mg/kg sazetidine-A (saz-A) or saline. *P < .05 using a Student's t-test. Male C57BL/6 mice n ¼ 14 per group. at 1, 2, and 3 mg/kg did not affect water or saccharin consumption in mice, and thus does not affect overall fluid intake nor consumption of a natural reward. This finding is consistent with studies of other nAChR drugs; for example varenicline does not affect operant responding for sucrose (Steensland et al., 2007; Wouda et al., 2011) or for food (Ginsburg and Lamb, 2014) at doses that reduce operant responding for alcohol (0.5e1 mg/kg). However, varenicline will reduce sucrose consumption in rats at higher doses (2 mg/kg) (Shariff et al., 2016) . Mecamylamine has only been shown to reduce oral sucrose consumption at high doses that also reduce locomotor activity (Ford et al., 2009) . One possible explanation for the lack of effect of sazetidine-A on nicotine consumption compared to varenicline is that varenicline exhibits reinforcing properties and discriminative stimulus properties in nicotine-trained rats compared with sazetidine-A (Paterson et al., 2010) . In that study, dose-dependent peak responding for varenicline was higher than that of nicotine or sazetidine-A, thus we speculate that varenicline may better substitute for the rewarding effects of nicotine than sazetidine-A.
One advantage of our oral co-consumption models is the ability to easily test the effects of forced abstinence and re-introduction on concurrent drug consumption. While clinical studies testing the effect of nAChR drugs on alcohol re-instatement are limited, studies have shown that varenicline reduces cue-induced relapse to alcohol seeking in rats (Funk et al.; Lacroix et al., 2017; Wouda et al., 2011) , and inhibits increases in alcohol consumption in mice induced by repeated bouts of abstinence (Lacroix et al., 2017) . Additionally, mecamylamine was shown to block deprivationinduced increases in alcohol consumption in rats (Kuzmin et al., 2009 ). We performed two separate experiments investigating the effect of sazetidine-A on alcohol and nicotine co-consumption following 1 week of forced abstinence from either alcohol or nicotine. In the alcohol abstinence experiment, sazetidine-A significantly reduced consumption of alcohol, but not nicotine, when it was administered immediately before the alcohol bottle was re-introduced. Thus, sazetidine-A had a similar effect as mecamylamine and varenicline in that it attenuated alcohol consumption after abstinence, but differed in that nicotine consumption was not reduced. We found similar results in the nicotine abstinence procedure, in which sazetidine-A again reduced consumption of alcohol, but not nicotine, when it was administered immediately before the nicotine bottle was re-introduced.
Because our two-and three-bottle choice procedures are chronic consumption experiments, we tested the effect of sazetidine-A on acute alcohol consumption in a binge drinking-inthe-dark procedure (Rhodes et al., 2005) in order to determine whether neuromolecular changes that occur as a result of chronic alcohol consumption may be required for sazetidine-A to reduce alcohol consumption. Chronic alcohol consumption has been shown to alter the expression of genes involved in neuron excitability (Allan and Harris, 1987; Morrisett and Swartzwelder, 1993) , neurotransmitter release (Diaz et al., 2011; Kalluri et al., 1998) , signal transduction (Neasta et al., 2011) inflammation (Blednov et al., 2011 (Blednov et al., , 2012 , and stress responses (McClintick et al., 2013) (for reviews, see (Costin and Miles, 2014; Farris and Miles, 2012) ), all of which could potentially alter the effect of sazetidine-A on consumption. Additionally, both varenicline (Hendrickson et al., 2010; Patkar et al., 2016) and mecamylamine (Hendrickson et al., 2009 ) have also been shown to reduce binge alcohol consumption in mice. In this procedure, which consists of a total of four bouts of alcohol consumption, we found that mice pretreated with sazetidine-A 1 h prior to an alcohol binge session consumed less alcohol than saline-treated controls. Therefore the ability of sazetidine-A to reduce alcohol consumption does not depend on chronic consumption.
Alcohol consumption increases acetylcholine (ACh) levels in the VTA (Larsson et al., 2005) . Imbalances in DA and ACh levels in the mesolimbic neurocircuitry are thought to contribute to increased tremor, autonomic hyper-excitability, and convulsions during alcohol withdrawal (Metten and Crabbe, 2005; Rada et al., 2004) .
Since alcohol interacts with a4b2 nAChRs (Aistrup et al., 1999; Cardoso et al., 1999) , and nAChRs act to modulate neurotransmitter release (Alkondon and Albuquerque, 2001; MacDermott et al., 1999) , it is likely that nAChRs play a role in neuronal hyperexcitability during alcohol withdrawal. Indeed, mice with genetic mutations in the a4 nAChR subunit gene or with a genetic deletion of the b2 subunit exhibit altered HIC scores during alcohol withdrawal (Butt et al., 2004) . We measured HIC scores during acute alcohol withdrawal and found that mice pretreated with sazetidine-A exhibited significantly reduced HIC scores during peak alcohol withdrawal compared to saline pretreatment. Significant differences between sazetidine-A-treated mice and controls were observed at 9e12 h post alcohol injection, corresponding to 10e13 h post sazetidine-A pretreatment. Our observation that sazetidine-A reduces alcohol withdrawal HICs at 9e12 h after alcohol injection is consistent with the timing of reduced alcohol HIC scores reported in other studies in rodents (Farook et al., 2008; Kotlinska et al., 2011; Martinez et al., 2016) . Sazetidine-A (1 mg/kg) has been shown to occupy over 50% of brain b2-containing nAChRs for at least 8 h, with 20% occupancy after 24 h (Caldarone et al., 2011) , so it is likely that sazetidine-A acts on the a4b2 nAChRs for the duration of the alcohol withdrawal experiment. We speculate Fig. 6 . Sazetidine-A reduces handling-induced convulsions during alcohol withdrawal. A) Average HIC scores during alcohol withdrawal in mice after pretreatment with 1 mg/ kg sazetidine-A or saline. *P < .05, **P < .01, ***P < .001, ****P < .0001 versus within-group baseline, and f P < .05, ff P<.01 versus saline treatment. B) Average alcohol withdrawal severity over 10 h *P < .05. Male C57BL/6 mice n ¼ 7e8 per group. that long-term desensitization by the a4b2 partial agonist sazetidine-A reduced alcohol withdrawal scores by decreasing cholinergic tone. Interestingly, DHbE, which does not reduce alcohol consumption also does not reduce alcohol HIC scores (Goldstein, 1973) . This is the first report of a nAChR drug that reduces alcohol consumption in both chronic and acute consumption procedures without affecting nicotine consumption, and implicates an alcoholspecific role for the nAChRs. The identity of the nAChR subtypes critical for alcohol addiction mechanisms the neural circuits they are involved in remain unclear. Sazetidine-A fully activates the a4 2 b2 3 stoichiometry (Xiao et al., 2006; Zwart et al., 2008) and has negligible activity at a4 3 b2 2 nAChRs (Campling et al., 2013; Eaton et al., 2014; Zwart et al., 2008) . Sazetidine-A also has full agonist effects at the a7 and a3b4 nAChRs, and partial agonist effects at the a4b4* and a6b2* nAChRs (Brown and Wonnacott, 2015; Campling et al., 2013; Kuryatov and Lindstrom, 2011) . Similar to sazetidine-A, varenicline is a partial agonist at a4b2 (Coe et al., 2005) , a full agonist at a7 and a3b4* and a partial agonist at a6b2* and a3b2* receptors (Campling et al., 2013; Grady et al., 2010; Mihalak et al., 2006; Rollema et al., 2007) . It is possible that the differences observed in the effects of varenicline and sazetidine-A on reducing nicotine consumption are mediated by different nAChR subunits, as the role of individual subunits within nicotine addiction neurocircuitry remains unclear, as well as differences in pharmacokinetics of varenicline and sazetidine-A in vivo. Moreover, the inability of DHbE (a b2* and b4* antagonist) to reduce alcohol consumption (Kuzmin et al., 2009; Le et al., 2000) , alcohol-induced accumbal DA release (Larsson et al., 2002) , and alcohol-induced behaviors (Kamens and Phillips, 2008; Larsson et al., 2002; Lof et al., 2007) suggest that b2* and b4* nAChRs are not involved in alcohol consumption mechanisms. Lastly, varenicline is a potent agonist of the 5-hydroxytryptamine3 (5-HT 3 ) receptor (Lummis et al., 2011) , whereas the effect of sazetidine-A on the 5-HT 3 receptor is unknown. As 5-HT 3 receptors co-localize with nAChRs in the dopaminergic terminals in the striatum (Nayak et al., 2000) and genetic differences in the human 5HT 3AB receptor have been associated with nicotine dependence (Yang and Li, 2014) , the interaction of varenicline with 5-HT 3 receptors may also account for its ability to reduce nicotine consumption.
Genetic deletions of various nAChR subunits have revealed the critical importance of specific subunits in alcohol consumption in mice. Mice with genetic deletion of the a4 nAChR subunit consume significantly less alcohol than wild-type controls (Hendrickson et al., 2011; Kamens et al., 2010) , and do not develop alcohol conditioned place preference (CPP) (Liu et al., 2013) . The a4 nAChR subunit is critical for the reduction of alcohol consumption by varenicline, since varenicline does not reduce alcohol consumption in a4 KO mice (Hendrickson et al., 2010) . Additionally, the a6 nAChR subunit is critical in mediating the rewarding effects of alcohol, as a6 KO mice have reduced alcohol-induced dopaminergic activation (Liu et al., 2013) and reduced expression of alcohol CPP (Guildford et al., 2016) . Mice with a hypersensitive a6 nAChR knock-in subunit consume more alcohol than their wild-type counterparts (Powers et al., 2013) . Furthermore, a7 KO mice have reduced baseline alcohol consumption, which is potentiated by varenicline (Kamens et al., 2010) , and display increased sensitivity to alcohol-induced hypothermia, loss of righting reflex, and hyperlocomotion (Bowers et al., 2005) . In contrast, the b2 nAChR subunit does not appear to be important in alcohol consumption, as genetic deletion of the b2 subunit does not affect alcohol consumption or preference (Butt et al., 2005; Dawson et al., 2013; Kamens et al., 2010) . This is intriguing, as the b2 subunit is a major binding partner for the a4 and a6 subunits (for reviews, see (Albuquerque et al., 2009; Gotti et al., 2006) ). Regarding nicotine consumption, the a4, a6, and b2 subunits are critical for nicotine reinforcement, as mice with genetic deletions for these subunits self-administer significantly less nicotine than their wild-type counterparts (Picciotto et al., 1998; Pons et al., 2008) . Since the a4 subunit appears to be critical for both alcohol and nicotine consumption, but the b2 subunit appears to be critical for only nicotine consumption, nAChR subtypes other than a4b2 may play a role in the alcohol-specific effect of sazetidine-A. Interestingly, the a7 subunit does not play a major role in nicotine consumption, as a7 KO mice display no change in nicotine self-administration (Pons et al., 2008) , suggesting that the a7 subunit is a potential candidate that mediates the alcoholspecific effect of sazetidine-A. The a7 antagonist methyllycaconitine (MLA) does not reduce alcohol consumption (Kuzmin et al., 2009 ), but as varenicline and sazetidine-A are both agonists at the a7 receptor, activation of a7 nAChRs may be required for the reduction of alcohol consumption.
Conclusions
We found that sazetidine-A reduces alcohol but not nicotine consumption in male and female C57BL/6 mice using models of voluntary, oral consumption procedures. In two-bottle choice procedures for alcohol or nicotine consumption, 1 mg/kg sazetidine-A reduced consumption of alcohol but not nicotine in male and female mice compared with saline-treated controls. Similarly, in a three-bottle choice co-consumption procedure in which both alcohol and nicotine were available, sazetidine-A reduced alcohol but not concurrent nicotine consumption. The specific reduction in alcohol consumption was also observed after a period of forced alcohol or nicotine abstinence. Sazetidine-A reduced acute alcohol consumption in a binge, drinking-in-thedark procedure. Thus, our data show that the ability of sazetidine-A to reduce alcohol consumption is not dependent on chronic alcohol exposure, abstinence, or the presence of nicotine. Finally, we demonstrate that sazetidine-A reduces alcohol withdrawal symptoms in the form of handling-induced convulsions. It will be useful to determine the specific nAChR subtypes and neurocircuits that are required for the alcohol-specific effect of sazetidine in future studies.
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